Below are the most recent publications written about "Lymphoma, T-Cell, Peripheral" by people in Profiles.
-
Manini N, Davidow K, Conard K, Powell J. Hematopoietic Bone Marrow Transplant to Treat Systemic EBV-positive T-cell Lymphoma of Childhood. J Pediatr Hematol Oncol. 2024 03 01; 46(2):e208-e211.
-
Ruan J, Zain J, Palmer B, Jovanovic B, Mi X, Swaroop A, Winter JN, Gordon LI, Karmali R, Moreira J, Petrich AM, Pro B. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 2023 10 10; 7(19):5771-5779.
-
Poon L, de Leval L, Ng SB, Song Y, Pro B, Savage KJ, Ruan J, Mehta-Shah N, Vose JM. Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma. Hematol Oncol. 2024 Nov; 42(6):e3191.
-
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022 03; 33(3):288-298.
-
Hong J, Johnson WT, Kartan S, Gonsalves AS, Fenkel JM, Gong JZ, Porcu P. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). Curr Oncol. 2021 12 02; 28(6):5067-5072.
-
Mina A, Pro B. T time: Emerging and new therapies for peripheral T-cell lymphoma. Blood Rev. 2022 03; 52:100889.
-
Nizamuddin I, Galvez C, Pro B. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. Semin Hematol. 2021 04; 58(2):85-94.
-
Pearse WB, Pro B. Diagnosis, Risk Stratification, and Treatment of Peripheral T-Cell Lymphomas: Past and Present. Cancer J. 2020 May/Jun; 26(3):253-259.
-
Allen PB, Pro B. Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes. Curr Oncol Rep. 2020 04 16; 22(5):44.
-
Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematol. 2020; 143(1):40-50.